Revenue
2019
2020
2021
2022
2023
2024
2025
Lyell Immunopharma, Inc. (LYEL)
Price$14.37Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $36,000 | $61,000 | $130,000 | $84.7M | $10.7M | $7.8M | $657,000 |
| Research & development | $158.7M | $171.6M | $182.9M | $159.2M | $138.7M | $182.2M | $63.6M |
| Operating expenses | $269.4M | $358.8M | $247.1M | $271.7M | $225.4M | $219.7M | $102.7M |
| Operating income | −$269.4M | −$358.8M | −$247.0M | −$187.1M | −$214.8M | −$211.9M | −$102.1M |
| Operating margin | −748,344.44% | −588,122.95% | −190,006.15% | −220.89% | −2,016.68% | −2,732.56% | −15,538.66% |
| EBITDA | −$257.9M | −$339.1M | −$226.8M | −$169.0M | −$201.2M | −$207.6M | −$100.8M |
| EBITDA margin | −716,291.67% | −555,940.98% | −174,429.23% | −199.61% | −1,888.75% | −2,677.19% | −15,347.49% |
| Net income | −$274.4M | −$343.0M | −$234.6M | −$183.1M | −$250.2M | −$204.5M | −$129.4M |
| Net profit margin | −762,355.56% | −562,285.25% | −180,486.15% | −216.24% | −2,349.47% | −2,636.31% | −19,692.09% |
| Basic EPSper basic share | -$16.06 | -$26.23 | -$18.70 | -$14.80 | -$36.80 | -$313.80 | -$480.80 |
| Diluted EPSper diluted share | -$16.06 | -$26.23 | -$18.70 | -$14.80 | -$36.80 | -$313.80 | -$480.80 |
Owners
Reported shareholders
≈13.88%of listed shares
BERNS PAUL L / Burow Kristina / ARCH Venture Partners XIII, LLC / ARCH Venture Partners XIII, L.P. / BYBEE CLINTON / GILLIS STEVEN / NELSEN ROBERT / ARCH Venture Fund XIII, L.P. / CRANDELL KEITH3.25M shares · Mar 6, 2026
View holders
| Holder | % owned |
|---|---|
BERNS PAUL L / Burow Kristina / ARCH Venture Partners XIII, LLC / ARCH Venture Partners XIII, L.P. / BYBEE CLINTON / GILLIS STEVEN / NELSEN ROBERT / ARCH Venture Fund XIII, L.P. / CRANDELL KEITH | ≈13.88%3.25M shares |
ARCH Venture Management, LLC | 13.88%3.25M shares |
ARCH Venture Partners IX Overage, L.P. / ARCH Venture Partners IX, L.P. / ARCH Venture Partners IX, LLC / ARCH Venture Fund IX, L.P. / ARCH Venture Fund IX Overage, L.P. | ≈13.88%3.25M shares |
Innovative Cellular Therapeutics Holdings Ltd | ≈12.54%2.93M shares |
GSK plc | 6.47%1.51M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.36%786.77K shares |
Orland Properties Ltd | 3.23%754.7K shares |
BlackRock, Inc. | 3.10%724.34K shares |
Almitas Capital LLC | 2.48%581.41K shares |
Foresite Capital Management V, LLC | 2.04%476.39K shares |
MILLENNIUM MANAGEMENT LLC | 1.57%367.47K shares |
Opaleye Management Inc. | 1.47%344.03K shares |
venBio Partners LLC | 1.44%337.7K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.33%310.64K shares |
Alphabet Inc. | 1.25%293.26K shares |
Klausner Richard | —190.56K shares |
STATE STREET CORP | 0.79%185.32K shares |
Lang Matthew | ≈0.69%162.5K shares |
HSG Holding Ltd | 0.65%152.3K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.56%130.19K shares |
Percentages use 23.4M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 10, 2026Form 4 | Shook DavidChief Medical Officer | SellCommon Stock | 2.0K | $12.64 | $25.0K | 20.9K |
| May 11, 2026Form 4 | Bulis Veronica SanchezVP, Corporate Controller | SellCommon Stock | 217 | $18.91 | $4.1K | 15.4K |
| May 11, 2026Form 4 | Lee Gary K.Chief Scientific Officer | SellCommon Stock | 130 | $18.92 | $2.5K | 17.8K |
| May 11, 2026Form 4 | Hill Stephen J.Chief Operating Officer | SellCommon Stock | 89 | $18.92 | $1.7K | 17.9K |
| May 11, 2026Form 4 | Seely LynnPresident and CEO | SellCommon Stock | 388 | $18.91 | $7.3K | 73.9K |